|Articles|June 15, 2003
- BioPharm International-06-01-2003
- Volume 16
- Issue 6
Small Biopharms Face Unique Challenges: Outsourcing in Early-Stage Drug Development
by Bruce Babbitt, PAREXEL International, JanHasker Jonkman, and Paul McKim By partnering with external drug development service providers, small biopharmaceutical start-ups can move their products out of the lab and into clinical development more efficiently.
Advertisement
Articles in this issue
over 22 years ago
SOX in the Boardroom: What the Sarbanes?Oxley Act Means to Youover 22 years ago
Inside Washington: Reshaping Biotech Drug Developmentover 22 years ago
BioTrends: M&A MalaiseNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
